Repotrectinib

FDA approvals rise 49% in 2023; CRISPR’s gene editing therapy sees light of day

In 2022, when the US Food and Drug Administration (FDA) was reeling under the impact of the pandem

Top 100 pharma & biotech deals in 2022

The pandemic years haven’t been great for dealmaking. Our analysis of top 10 biopharma M&A tra